

Global Consultation on the Programmatic Management of Latent Tuberculosis Infection

Date: 27-28 April 2016

Venue: Hotel President, Seoul, Republic of Korea

Agenda

Wednesday 27 April 2016

Opening session	
8:00–8:30	Registration
8:30–9:00	Opening Ceremony <i>Mario Raviglione (Director, Global TB Programme, WHO)</i> <i>Un-Yeong Go (Director, Center for Disease Prevention and Korean Network for Organ Sharing, KCDC)</i> <i>Sun Dae Song (Chairman of the Board, International Tuberculosis Research Center)</i> <i>Deok-cheol Kwon (Assistant Minister for Healthcare Policy, Ministry of Health & Welfare)</i>
Objective 1: Identify best practices, challenges, and opportunities in the implementation of programmatic management of LTBI for both high and low TB burden countries. Co-Chair: <i>Mario Raviglione (WHO)/ Sun Dae Song (ITRC)</i>	
9:00-9:15	<u>Programmatic management of LTBI- a two pronged approach for ending the TB epidemic</u> <i>Haileyesus Getahun (WHO)</i>
9:15-9:30	<u>Republic of Korea: progresses, challenges, and the way forward</u> <i>Un-Yeong Go (KCDC)</i>
9:30-9:45	<u>Ethiopia: experience on scaling up LTBI management for people living with HIV and child household contacts < 5years</u> <i>Blen Ayele (NTP, Ethiopia)</i>
9:45-10:00	Open discussion
10:00-10:30	Tea break
Objective 2: Define mechanism for monitoring and evaluation of the programmatic implementation of the LTBI management. Co-Chair: <i>Haileyesus Getahun (WHO)/ Howard Njoo (Public Health Agency of Canada)</i>	
10:30-10:45	<u>Monitoring and evaluating LTBI management: standard indicators and system</u> <i>Alberto Matteelli (University of Brescia, Italy)</i>
10:45-11:00	<u>What are key ingredients of success and remaining challenges for monitoring and evaluation</u> <i>Tan Eang Mao (NTP, Cambodia)</i>
11:00-11:15	<u>Key lessons from the Netherlands for other low burden and resource-rich countries</u> <i>Gerard de Vries (KNCV, The Netherlands)</i>
11:15-12:00	Open discussion
12:00-13:00	Lunch
13:00-13:10	Introduction to Market Place
13:10-16:00	<p style="text-align: center;">Moderated poster presentation and discussion (Market place) <i>For free exchange of country experiences on programmatic management of LTBI and identification of best practices, challenges, solutions, and opportunities.</i></p> <ul style="list-style-type: none"> • Station-1: <u>Armenia, Indonesia, Philippines</u> <i>(Moderator: Andrei Dadu, Rapporteur: Indonesia)</i> • Station-2: <u>Mozambique, Swaziland, Zimbabwe</u> <i>(Moderator: Kefas Samson, Rapporteur: Zimbabwe)</i> • Station-3: <u>Japan, Malaysia, Republic of Korea</u> <i>(Moderator: Nobuyuki Nishikiori, Rapporteur: Malaysia)</i> • Station-4: <u>Australia, The Netherlands, Portugal</u> <i>(Moderator: Knut Lonnoth, Rapporteur: Portugal)</i>
16:00-16:30	Tea break
16:30-17:30	Plenary presentation of key lessons learnt and discussions from market place <i>Presenters: <u>Indonesia, Zimbabwe, Malaysia, and Portugal</u></i>
18:00-20:00	Reception

Thursday, 28 April 2016

Diagnosis and Treatment of LTBI			
Co-Chair: Janet Ginnard (UNITAID)/Tae-Sun Shim (Asan Medical Center)			
8:30-8:45	Programmatic options and challenges for LTBI diagnosis and treatment in low and high TB burden settings. <i>Ibrahim Abubakar (University College London, UK)</i>		
8:45-8:55	Diagnosis and treatment of LTBI: experience from South Africa <i>Lindiwe Mvusi (NTP, South Africa)</i>		
8:55-9:05	Diagnosis and treatment of LTBI: experience from Norway <i>Brita Askeland Winje (Norwegian Institute of Public Health, Norway)</i>		
9:05-9:45	Commentary and discussion Verbal commentary: what are the challenges for nationwide scale up of LTBI diagnosis and treatment? <ul style="list-style-type: none"> • <i>Cindy Toms (NTP, Australia)(5 min)</i> • <i>Beatrice Mutayoba (NTP, Tanzania)(5 min)</i> • <i>Robert Horsburgh (Boston University School of Public Health, USA)(5 min)</i> 		
Objective 3: Review the landscape of research including ongoing clinical trials of LTBI treatments and identify potential impact and implementation gaps.			
Co-Chair: Enos Masini (NTP Kenya)/ Zelalem Temesgen (Mayo Clinic)			
9:45-10:00	LTBI diagnosis and treatment research landscape and gaps <i>Richard Chaisson (Johns Hopkins University, USA)</i>		
10:00-10:40	Special commentary and discussion <ul style="list-style-type: none"> • Phase 3 results of a novel skin test for LTBI - Peter Andersen (Statens Serum Institut, Denmark) (6 min) • Operational challenges to conduct LTBI studies - Gavin Churchyard (Aurum Institute, South Africa) (6 min) • Role of national TB programme in LTBI research - Van Hung (NTP, Viet Nam) (6 min) • What is missing to attract young researchers for LTBI - Carina Marquez (UCSF, USA) (6 min) 		
10:40-11:00	Tea break		
11:00-11:10	Introduction to break-out session		
11:10-13:00	<i>The objective of this session is to discuss specific actions and technical assistance needs to address bottlenecks and challenges identified during the preceding sessions.</i>		
	<table border="0"> <tr> <td style="vertical-align: top;"> <p>Group 1 (High TB burden countries) Moderator: Chawetsan Namwat (Thailand) Rapporteur: Beatrice Mutayoba (Tanzania) Secretariat: Yohhei Hamada (WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child household contacts <5 years.</p> </td> <td style="vertical-align: top;"> <p>Group 2 (Low TB burden countries) Moderator: Ibrahim Abubakar (UK) Rapporteur: Raquel Duarte (Portugal) Secretariat: Fatema Kazi(WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child and adult household contacts -Clinical risk groups: (patients initiating anti-TNF treatment; patients on dialysis; patients preparing for transplantation; patients with silicosis)</p> </td> </tr> </table>	<p>Group 1 (High TB burden countries) Moderator: Chawetsan Namwat (Thailand) Rapporteur: Beatrice Mutayoba (Tanzania) Secretariat: Yohhei Hamada (WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child household contacts <5 years.</p>	<p>Group 2 (Low TB burden countries) Moderator: Ibrahim Abubakar (UK) Rapporteur: Raquel Duarte (Portugal) Secretariat: Fatema Kazi(WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child and adult household contacts -Clinical risk groups: (patients initiating anti-TNF treatment; patients on dialysis; patients preparing for transplantation; patients with silicosis)</p>
<p>Group 1 (High TB burden countries) Moderator: Chawetsan Namwat (Thailand) Rapporteur: Beatrice Mutayoba (Tanzania) Secretariat: Yohhei Hamada (WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child household contacts <5 years.</p>	<p>Group 2 (Low TB burden countries) Moderator: Ibrahim Abubakar (UK) Rapporteur: Raquel Duarte (Portugal) Secretariat: Fatema Kazi(WHO)</p> <p><i>Focus risk groups:</i> -People living with HIV -Child and adult household contacts -Clinical risk groups: (patients initiating anti-TNF treatment; patients on dialysis; patients preparing for transplantation; patients with silicosis)</p>		
13:00-14:00	Lunch		
14:00-15:00	Group work presentations by rapporteurs and plenary discussions <i>Beatrice Mutayoba (NTP, Tanzania)/ Raquel Duarte (NTP, Portugal)</i>		
15:00-15:30	Tea break		
Objective 4: Identify opportunities and next steps to the implementation of programmatic management of LTBI.			
Co-Chair: Mario Raviglione (WHO)/ Haileyesus Getahun (WHO)			
15:30-15:40	Enabling scale-up of preventive strategies for TB: UNITAID's role in funding opportunities <i>Janet Ginnard (UNITAID, Switzerland)</i>		
15:40-15:50	Generating demands and activism for LTBI <i>Mike Frick (Treatment Action Group, USA)</i>		
15:50-16:10	Discussion		
16:10-17:30	General moderated plenary discussions on next steps: technical assistance needs, research gaps, and key country level actions		
17:30-17:45	Closing		